April 09, 2020 + Jessica Di Palo
5 Min read
The $50 million round will support the TytoCare to continue to scale business activities globally, as well as respond to the increase in demand for their digital health solutions.
MTIP, the pan-European specialist Healthtech investor, took part in the newest financing round for Fund I Portfolio Company TytoCare. The $50 million round will support the Company to continue to scale business activities globally, as well as respond to the increase in demand for their digital health solutions.
In these troubling times caused by COVID-19, when we all face social isolation and governments impose restrictions upon us, we need to constantly monitor these impacts on our selected portfolio companies. As the demand for telehealth is accelerating, we are proud that TytoCare, the healthcare industry’s first all-in-one modular device and telehealth platform for on-demand, remote medical examinations, closed a financing round of $50 million, bringing the Company’s total capital raised to more than $105 million.
TytoCare’s product TytoHome, an easy to use toolkit that offers on-demand medical exams for patients, is a unique telehealth diagnostic solution. The Israeli digital health Company allows patients to self–monitor, and the data to be sent remotely to physicians, allowing them to oversee patients without exposure to a disease. In Switzerland the health inscurance Company SWICA will be testing TytoHome with 2000 of their customers until the end of 2020. The insurer reports that their pilot project has been very popular and that all devices have been successfully assigned.
«This round of financing will allow Tyto Care to focus even more on the needs of patients to develop new devices that build on their telehealth platform», said Dr. Christoph Kausch Managing Partner of MTIP. He adds: «Furthermore, we see the Company’s development as a confirmation of our investment thesis». MTIP recognized several years ago that the system was not able to keep up with demand, and the healthcare sector would need to innovate and leverage new technologies to continue to operate at a sustainable level. One of the key pillars of MTIP’s investment thesis is the need for decentralization. In an environment where we are all isolated in our homes, it is companies like TytoCare that are of particular necessity. MTIP is confident in the defensiveness of the Healthtech sector and our ability to continue to make successful investments throughout the cycle. It is with great pleasure that we look back on the previous relationship between TytoCare and MTIP and look forward to how this symbiosis will continue to grow in the future.
As TytoCare CEO and Co-founder Dedi Gilad noted: «MTIP has played and will continue to play a vital role in opening doors and creating potential partnerships throughout Europe. Building on the success and excitement for TytoCare in the US, we are pleased to be partnering with such a knowledgeable digital health investor whose unique position will help us further transform telehealth and reach more homes around the globe, especially in Europe.»
Digital healthcare: patient-first?
Digital Healthcare Report 2021 in collaboration with Dealroom and INKEF Capital
SFDR – How does MTIP approach the EU’s Sustainable Disclosure Regulation?
New SFDR obligations
MTIP Announces Strong First Closing of Fund II to drive Healthtech Innovation
First Closing of Fund II
How to pitch to a healthtech Investor
MTIP invests in Koa Health to make mental health treatment more accessible
New investment in Koa Health
MTIP scored fantastic grades in the UNPRI assessment report of 2020
UNPRI Report grades 2020
4 Health VCs Share Their Business Priorities and What is Next
MTIP invests in Trialbee
New investment in Trialbee
TytoCare closes $50 million round as the demand for telehealth accelerates
TytoCare closes new round
The digital healthtech sector is expanding – and so are we!
Two new empolyees start in April
MTIP has sucessfully exited Blueprint Genetics
Blueprint exit January 2020
New MTIP investment in Oviva
New investment in Oviva
Whitepaper: A positive prognosis for the future of healthtech
Our first Whitepaper
Elite Summit 2019 – Interview with our Managing Partner Christoph Kausch
Elite Summit 2019
MTIP Healthcare Clinic 2019
Healthcare clinic 2019
New MTIP investment in Cynerio
New investment in Cynerio
MTIP invests in Lumeon Ltd.
New investment in Lumeon
Magenverkleinerung mit der Handnähmaschine
Nitinotes news paper article
New MTIP investment in Quanta Dialysis Technologies
New investment in Quanta
MTIP’s Healthcare Clinic 2018
Healthcare Clinic 2018
Interview with Christoph Kausch in biotechandmoney
New MTIP investment – Nitinotes Series A Round
New investment in Nitinotes
New investment in an Israeli based digital health company TytoCare
New investment in TytoCare
MTIP joins United Nations-supported Principles for Responsible Investments
MTIP signs Principles for Responsible Investments
MTIP invests in Blueprint Genetics
new investment in Blueprint Genetics